Literature DB >> 25544892

Pseudomonas infection in antibody deficient patients.

Sai S Duraisingham, Steven Hanson, Matthew Buckland, Sofia Grigoriadou, Hilary J Longhurst.   

Abstract

Pseudomonas aeruginosa (PA) is commonly isolated from the respiratory secretions of antibody deficiency patients, but the significance of this has not been well studied. We have reviewed our adult antibody deficiency cohort of 179 patients and assessed the prevalence and characteristics of PA infection and the effects of early antibiotic eradication treatments. Of the 34 patients with PA, 55.9% (19) underwent successful eradication and were infection-free, 38.2% (13) had intermittent infection, and 5.9% (2) had chronic PA. PA infection was significantly associated with bronchiectasis (p < 0.0001), with 36.1% (22 out of 61) of patients with bronchiectasis developing a PA infection. Infection status was also significantly associated with chronic sinusitis (p < 0.0001). Most treated PA exacerbations were symptomatic and with colony counts of ≥1000 cfu/ml. Current eradication protocols used at our center involve early treatment at first positive isolate with ciprofloxacin for 3 weeks and nebulized colomycin for 3 months, and if eradication fails, intravenous ceftazidime and gentamycin or colomycin is administered for 2 weeks. Continued sputum surveillance and early eradication treatments upon positive PA culture may help to limit chronic PA infection in antibody deficiency patients.

Entities:  

Keywords:  Pseudomonas; bronchiectasis; immunodeficiency; infection

Year:  2014        PMID: 25544892      PMCID: PMC4271816          DOI: 10.1556/EUJMI-D-14-00026

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  16 in total

1.  Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.

Authors:  C B Wilson; P W Jones; C J O'Leary; D M Hansell; P J Cole; R Wilson
Journal:  Eur Respir J       Date:  1997-08       Impact factor: 16.671

2.  Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients.

Authors:  Felix Ratjen; Hanna Walter; Maria Haug; Christoph Meisner; Hartmut Grasemann; Gerd Döring
Journal:  Pediatr Pulmonol       Date:  2007-03

3.  Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

Authors:  B Frederiksen; C Koch; N Høiby
Journal:  Pediatr Pulmonol       Date:  1997-05

4.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

5.  Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre.

Authors:  M Proesmans; W Balinska-Miskiewicz; L Dupont; X Bossuyt; J Verhaegen; N Høiby; K de Boeck
Journal:  Eur Respir J       Date:  2006-05       Impact factor: 16.671

6.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

Authors:  Miguel Angel Martínez-García; Juan-Jose Soler-Cataluña; Miguel Perpiñá-Tordera; Pilar Román-Sánchez; Joan Soriano
Journal:  Chest       Date:  2007-11       Impact factor: 9.410

7.  Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.

Authors:  C R Hansen; T Pressler; N Høiby
Journal:  J Cyst Fibros       Date:  2008-08-09       Impact factor: 5.482

8.  The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008.

Authors:  B Gathmann; B Grimbacher; J Beauté; Y Dudoit; N Mahlaoui; A Fischer; V Knerr; G Kindle
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

9.  Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.

Authors:  M Ballmann; P Rabsch; H von der Hardt
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

10.  Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods.

Authors:  Tacjana Pressler; Ferenc Karpati; Marta Granström; Per Kristian Knudsen; Anders Lindblad; Lena Hjelte; Hanne V Olesen; Peter Meyer; Niels Høiby
Journal:  J Cyst Fibros       Date:  2008-10-05       Impact factor: 5.482

View more
  3 in total

1.  IL17-Producing γδ T Cells May Enhance Humoral Immunity during Pulmonary Pseudomonas aeruginosa Infection in Mice.

Authors:  Tingting Pan; Ruoming Tan; Meiling Li; Zhaojun Liu; Xiaoli Wang; Lijun Tian; Jialin Liu; Hongping Qu
Journal:  Front Cell Infect Microbiol       Date:  2016-12-06       Impact factor: 5.293

2.  Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group.

Authors:  S Jolles; S Sánchez-Ramón; I Quinti; P Soler-Palacín; C Agostini; B Florkin; L-J Couderc; N Brodszki; A Jones; H Longhurst; K Warnatz; F Haerynck; A Matucci; E de Vries
Journal:  Clin Exp Immunol       Date:  2017-08-25       Impact factor: 4.330

3.  Microbial profiles at baseline and not the use of antibiotics determine the clinical outcome of the treatment of chronic periodontitis.

Authors:  S Bizzarro; M L Laine; M J Buijs; B W Brandt; W Crielaard; B G Loos; E Zaura
Journal:  Sci Rep       Date:  2016-02-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.